AzTrials
AzTrials

Cardiac Resynchronisation Therapy (CRT)Nordic-CSPNCT07492979

Conduction System Pacing vs. Biventricular Pacing for Cardiac Resynchronization Therapy

A study testing HIS or LBBB -CRT and Conventional BiV-CRT in people with Cardiac Resynchronisation Therapy (CRT) and Heart Failure, run by Copenhagen University Hospital, Rigshospitalet at 5 sites in 4 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The NORDIC-CSP trial is an investigator-initiated, blinded, nordic RCT aimed at evaluating whether using direct pacing of the HIS bundle (HIS)-pacing or left bundle branch (LBB) pacing is superior to conventional biventricular pacing in reducing the incidence of the composite endpoint of death and non-planned HF… Read more about this study

Who is it for?
Ages 18 to 99 years
What is being tested?
HIS or LBBB -CRT and Conventional BiV-CRT
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,100 participants
Where
5 sitesin 4 countries
Study dates
17 Jun 2026to 1 Jul 2031
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • ≥18 years of age,
  • LVEF ≤ 35%,
  • NYHA Class II-IV (IV only outpatients),
  • optimized in medical treatment (OMT)
  • AND one of the following:
  • . LBBB according to AHA/ACC/HRS Scientific Statement from 2009 and ≥130ms or
Show all 10Show fewer
  • LBBB-like intraventricular conduction delay (IVCD) > 150ms or RV paced QRS and indication for upgrade to CRT (> 40% RV pacing) OR
  • ≥18 years of age,
  • LVEF ≤ 40 %
  • pacing indicated by AV-block and, thus, expected large percentage of ventricular pacing.

Who cannot join

  • recent acute myocardial infarction (AMI)
  • coronary artery bypass graft (CABG) (<3 months)
  • life expectancy <2 years, patients in hemodialysis
  • treatment with a cardiac implantable electronic device (CIED) is contraindicated.
  • Patients are excluded with regards to the MRI sub study if eGFR > 35 ml/min, in case or contrast allergy or certain metal implants.

Trial locations and contacts

5 sites in 4 countries. Contact the study team or a site near you to ask about taking part.

Niels Risum, MD, PhD contact

0045 35456995

niels.risum.01@regionh.dk

Michael Vinther, MD, PhD contact

0045 35456994

michael.vinther@regionh.dk

5 sites in 4 countries

Denmark2 sites, 2 recruiting
  • Dept. of Cardiology, Aarhus University Hospital, Aarhus

    Aarhus, 8200

    Jens Kristensen, MD, PhD, 0045 29410644, jens.kristensen@auh.rm.dk

    Not yet recruiting
  • Rigshospitalet, Copenhagen University Hospital

    Copenhagen, 2100

    Niels Risum, MD, PhD, 004535456995, nordic-csp.rigshospitalet@regionh.dk

    Michael vinther, MD, PhD, 004535456994, michael.vinther@regionh.dk

    Recruiting

Other trials in Denmark

Finland1 site, 1 recruiting
  • Dept of Cardiology, Meilahti Hospital, Helsinki

    Helsinki, 00290

    Jarkko Karvonen Karvonen, jarkko.karvonen@hus.fi

    Not yet recruiting

Other trials in Finland

Norway1 site, 1 recruiting
  • Haukeland Universitetssykehus

    Bergen, 5009

    Torbjørn Lunde, 0047 xxxxxxxx, torbjorn.lunde@gmail.com

    Not yet recruiting

Other trials in Norway

Sweden1 site, 1 recruiting
  • Sahlgrenska University Hospital

    Gothenburg

    Amar Taha, 0046 313427551, Amar.taha@vregionh.se

    Not yet recruiting

Other trials in Sweden

About this study

Official title: Nordic-CSP - a Randomized Nordic Study - Is Conduction System Pacing Superior Compared to Conventional BIV-CRT in Reducing the Death or Heart Failure-related Hospitalization in Patients With Heart Failure and Bundle Branch Block?

The NORDIC-CSP trial is an investigator-initiated, blinded, nordic RCT aimed at evaluating whether using direct pacing of the HIS bundle (HIS)-pacing or left bundle branch (LBB) pacing is superior to conventional biventricular pacing in reducing the incidence of the composite endpoint of death and non-planned HF hospitalization. The study will be conducted in the 4 CRT-centres in Denmark and 6-8 centres from countries Sweden, Norway and Finland.

Read the detailed description

In this investigator-initiated, blinded, nordic RCT, we will investigate conduction system pacing (CSP) in heart failure (HF) patients. We hypothesized that Cardiac Resynchronization Therapy (CRT) by HIS-pacing or LBB-pacing is superior compared to conventional biventricular (BIV)-CRT in reducing the incidence of the composite endpoint (Death and HF-hospitalization) in patients with symptomatic HF, with LVEF ≤ 35% and indication for CRT.

The Study is a collaboration between CRT centers in the Nordic countries with experience in CSP.

Randomization:

Randomization is conducted electronically using the CRF on the day of device implantation. A computer algorithm will randomly assign patients 1:1 to either the conventional method BIV-CRT or to "the new method" HIS/LBB-CRT.

Randomization will be stratified by the presence of a) true LBBB, b) other bundle branch block (BBB) and c) RV pacing. This will be performed by randomizing in blocks of 10 for LBBB and RV pacing/other bundle branch blocks. Block-randomization is used to ensure that each center includes a similar number of patients for each treatment arm.

The implanting physician is aware of group allocation to provide the correct treatment. Only the implanting physician can access this information in the CRF. The patients and study per-sonnel involved in end-point adjudication as well as all personnel performing imaging analy-sis are blinded to randomization. Follow-up is identical in the two treatment groups. All fol-low-up personnel are blinded to treatment assignment.

Implantation:

The RV electrode is preferentially placed in an RV septal position unless factors related to lead stability, electrical values, and defibrillation vector favor an apical position (at the discretion of the implanting physician). The atrial electrode is positioned at the preference of the implanting physician. With successful implantation of a lead for HIS- or LBB-pacing the physician may prefer to not implant a RV-lead to the septum. In that case, there is no need for a CRT pacemaker and a dual-chamber pacemaker can be implanted instead.

In the HIS-LBB group, CSP is performed according to current recommendations13. The leads allowed to implant in the HIS-LBB position are the ones that have received CE-approval for this indication.

Both HIS-pacing or LBB-pacing can be attempted as first approach at the physician's discretion using available leads both stylet-driven or non-stylet driven and if necessary, guiding from an electrophysiology catheter is used.

HIS-pacing: An approximate ratio of 1:4 between A and V with a clear His deflection is iden-tified and His-capture confirmed. If the threshold for capture of His and the left bundle branches is too high (> 2 V at 1 ms duration) assessed by the operator, the lead should be replaced. If it is not possible to achieve selective or non-selective HIS pacing with bundle branch block correction at a threshold below or equal to 2 V at 1 ms in duration, an attempt to implant the electrode to achieve direct left bundle branch pacing (LBBP) is performed instead.

LBB-pacing: LBB-pacing is performed by moving the sheath a few centimeter further towards the apex of the right ventricle, ensuring contact to the septum. The electrode is screwed into the septum at an angle of -10⁰ to 40⁰ while monitoring current-of-injury (COI), impedance and pacing configuration (gradual emergence of a terminal R-wave in lead V1) until the left bundle branch area is activated and a right-sided bundle branch block pattern is obtained. The operator must attempt to confirm left conduction system capture by identify-ing one or more of the following criteria:

  • Fixation beats (PVC´s identical to the paced QRS-complex,)
  • Identification of LBB-potentials (> 15 ms before sensed QRS) and capture with RBBB-pattern during unipolar pacing on the LBB-lead. (Not in LBBB patients)
  • Transition of QRS patterns during threshold testing: ns-LBBP to s-LBBP : splitting of EGM and/or V1 RWPT (Rigth wave peak time)¬ by > 10 ms ns-LBBP to LVSP : V6 RWPT¬ by ≥ 15 ms V6 RWPT < 80 ms (LBBB, IVCD RBBB+fascicular block, wide escape rhythm, asystole) V6 -V1 interpeak interval > 44 ms QRS transition to s-LBBP during programmed stimulation

Or one of the following criteria considered likely to represent left conduction system capture:

V6 RWPT < 100 ms (LBBB, IVCD, RBBB + fascicular block, wide escape rhythm, asystole V6 -V1 interpeak interval > 33 ms QRS transition to LVSP during programmed stimulation V6 RWPT prolongation by 10-14 ms during threshold test

If the operator is not succesful, after several attempts, obtaining conduction system capture LVseptal capture (LVSP) can be accepted, with identification of a clearly defined R´ in V1. If only deep septal pacing can be obtained the lead can be left in place or removed at the op-erators discretion and an LV-lead has to be implanted to obtain either BIV-CRT or LOT-CRT.

.

Cross-over between intervention arms If neither HIS-pacing nor LBB-pacing is obtainable (none of the abovementioned criteria are met or Left Ventricular septal pacing cannot be obtained), the sheath is switched to a CS sheath instead and an LV electrode is placed as in a conventional CRT procedure. Finally, an atrial electrode is placed if there is not already a usable atrial electrode in place. In all pa-tients, signs of left conduction system capture identified are registered in the CRF.

In the BIV-CRT group, the LV lead is placed in the branch judged to be most suitable, prefer-entially in a posterolateral (2-5 o'clock in the mitral annulus), and mid-ventricular or basal, non-apical position (figure 2), after taking into consideration lead stability, pacing threshold and threshold for phrenic nerve stimulation. In general, multipolar (quadripolar) LV leads are used as first choice but the implanting physician may use a bipolar LV lead if a multipolar lead cannot be implanted. Balloon occlusion venography to visualize the CS and side branches is performed in all patients with a BIV-CRT. Supplementary selective venography may be used to visualize CS branches.

If it is not possible to place a LV -lead due to the anatomical conditions (lack of access to CS, lack of available side bundle branches or only possible to pace in the vena cordis media or vena cordis anterior) or due to unacceptable electrical measurements (best pacing threshold > 4 V at 1,0 msec, or phrenic nerve capture < 2 x lowest pacing threshold), the sheath is in-stead switched to a HIS sheath and electrode placement to the HIS bundle or LBB area is attempted using available sheaths and guide from electrophysiology catheter as outlined above. Again, it is up to the physician whether HIS- or LBB-pacing is attempted first. If it is not possible to achieve selective or non-selective HIS pacing with bundle branch block cor-rection at a threshold below or equal to 2.5 V at 1 ms in duration, an attempt is done to im-plant the electrode further into the ventricle and achieve direct left bundle branch pacing (LBB-CRT) instead. Finally, an atrial electrode is placed if there is not already a usable atrial lead in place. If it is not possible to place either an LV electrode, a HIS electrode or an elec-trode for LBB pacing, the attending physician must decide whether there is any indication for implantation of a transthoracic LV-lead.

Follow-up:

Clinical- and device check-ups are scheduled after 3-, 6- and 12 months, and annually thereafter according .This means that patients are in fact following the current standard regime after CRT-implantation with similar examinations including standard blood tests. However, in addition the patients will be asked to fill out questionnaires, that is the MLHFQ and PRO Questionnaires at baseline and 12 months. Remote monitoring is established for all pa-tients. Echocardiographic follow-ups are scheduled after 6- and 24 months. A 6MWT is per-formed 6 months. At each follow-up visit, medication is recorded and a ECG-12 is obtained upon patient arrival.

All patients are followed for a minimum of 2 years.

Being tested
HIS or LBBB -CRT, Conventional BiV-CRT
Keywords
Nordic-CSP, conduction system pacing, His-pacing, LBB-pacing, Biventricular pacing, Cardiac Resynchronization Therapy
Medical subject headings
Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • HIS or LBBB -CRTProcedure or surgery

    HIs pacing og LBB pacing at the implanteres discretion

  • Conventional BiV-CRTProcedure or surgery

    An LV-lead in a side-branch of the coronary sinus

Study groups in NCT07492979
Study groupRoleWhat they receive
LBB/HIS-CRT groupExperimentalNot described
Receives: Procedure: HIS or LBBB -CRT
BiV-CRT groupExperimentalNot described
Receives: Procedure: Conventional BiV-CRT

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Patients with a primary end-point

    The primary endpoint is a composite of time to death or first non-planned HF hospitalization. Non-planned HF is defined as an unplanned emergency room visit or admission to hospital due to worsening HF

    Measured: From enrollment and a minimum of 2 years or the primary outcome has occurred

Secondary outcomes (17)
  1. Patients experiencing device-related complications

    • Device-related complications. Periprocedural complication including electrode reoperation, pneumothorax, hemothorax, pericardial bleeding/tamponade and later complications (after 30 days post implantation) including LV/His electrode reoperation, change of device due to battery depletion and infection requiring extraction.

    Measured: From baseline until study completion, with a minimum of 2 years.

  2. Death

    All-cause death

    Measured: From baseline until study completion, with a minimum of 2 years

  3. Non planned HF-hospitalization

    Non-planned HF is defined as an unplanned emergency room visit or admission to hospital due to worsening HF

    Measured: From baseline until study completion with a minimum of 2 years

  4. Echocardiographic remodelling

    Echocardiographic end-points (re-modelling of the LV measured in mL: LVESV, LVEDV, LVEF). Echocardiographic response after 6 months and 24 months defined as decrease in left ventricular systolic volume ≥ 15% from baseline.

    Measured: From baseline to 6 months and 24 months

  5. Change in Dyssynchrony

    Change in dyssynchrony parameters myocardial work, longitudinal strain time-to-peak (ms), dyssynchrony patterns (categorized 1-4), apical rocking, septal flash (yes/No)

    Measured: evaluated at baseline, 6 months, 24 months

  6. Improvement in Clinical response

    Clinical response improvement in NYHA class by ≥ 1 or improvement in 6MWT (≥10% from baseline)" after 12 months.

    Measured: from baseline to 12 months

  7. Improvement in Six-min walking test.

    Functional response after 6 months defined as an increase in 6-min walking distance (meters) of ≥ 20% of the baseline value

    Measured: From baseline to 6 months

  8. Neurohormones

    Neurohormones, decline in NT-proBNP after CRT. pg/mL (picograms per milliliter) or ng/L (nanograms per liter)

    Measured: from baseline to 6 months

  9. Symptomatic response

    defined as a fall in NYHA class of ≥ 1

    Measured: From baseline to 6 months

  10. Life quality

    Minnesota Living with Heart Failure Qestionnaire. Comparison from baseline to 12 months follow-up in point score (0-105).

    Number of patients with improvements > 5 points and above 10 points are determined.

    Measured: from baseline to follow-up at 12 months

  11. ICD therapy

    ICD-therapy (time to first) of appropriate and inappropriate therapies, ATP or Shock

    Measured: from baseline to study completion, with a mnimum of 2 years

  12. Ventricular arrythmia

    Time to first VT (>135/min by ecg or device reading) or VF

    Measured: from baseline to completion of the study, with a mnimum of 2 years

  13. atrial fibrillation

    time to Persistent atrial fibrillation (> 7 days) and new-onset atrial fibrilllation (> 6 hours)

    Measured: from baseline to completion of the study with a minimum of 2 years

  14. time for implantation

    measured in minutes from skin incision to skin closure

    Measured: at implantation, from 30 minutes to 300 minutes

  15. x-ray

    • Use of X-ray dosage

    Measured: at implantation, from 1 minute to 150 minutes

  16. Electrodes

    number of electrodes used

    Measured: form implantation to completion of the study, a minimum of 2 years

  17. battery longevity

    • Battery longevity: The total battery longevity of each CRT-D was calculated as the sum of the patient's follow-up duration plus the estimated battery longevity remaining at the time of the last follow-up.

    Measured: from implantation to completion of the study, with a minimum of 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Mar 2026
  2. Study start17 Jun 2026
  3. Primary completion1 Mar 2031 (estimated)
  4. Study completion1 Jul 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
1,100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07492979
Sponsor's protocol ID
119231
Acronym
Nordic-CSP
Status last verified
Jul 2026
First submitted
10 Feb 2026
Last updated
28 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: not yet a plan for this

Questions about this trial

What is this clinical trial studying?

A study testing HIS or LBBB -CRT and Conventional BiV-CRT in people with Cardiac Resynchronisation Therapy (CRT) and Heart Failure, run by Copenhagen University Hospital, Rigshospitalet at 5 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 28 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in Denmark, Finland, Norway, Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Niels Risum, MD, PhD (0045 35456995, niels.risum.01@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Patients with a primary end-point (time frame: From enrollment and a minimum of 2 years or the primary outcome has occurred). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in